Found 178 clinical trials
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
This study aims to compare the efficacy and safety of lenalidomide plus CHOP (L-CHOP) versus CHOP alone in patients with previously untreated peripheral T-cell lymphoma (PTCL)
- 0 views
- 24 Jul, 2021
- 1 location
Study to Demonstrate Clinical Benefit of Lenalidomide and Dexamethasone (LENDER)
Recent prospective multicenter phase II study assessed the efficacy and tolerability of lower dose lenalidomide (15mg) and dexamethasone (20mg) in frail patients with relapsed or refractory MM
- 1 views
- 19 Apr, 2022
- 1 location
Lenalidomide in Combination With CHOP in Patients With Untreated PTCL
The prognosis of PTCL (except early stage ALK+ ALCL) is dismal. Previous study showed that single agent lenalidomide showed promising therapeutic activity in patients with relapsed or refractory
- 6 views
- 24 Jan, 2021
- 1 location
R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia (Ballondor)
A multicenter prospective phase II study of rituximab combined, lenalidomide, dexamethasone followed by lenalidomide maintenance in patients with newly diagnosed Waldenström's macroglobulinemia
- 21 views
- 23 Apr, 2022
- 1 location
Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL. (Lemon-C)
lenalidomide as one of the consolidation therapies for patients with primary central nervous system lymphoma (PCNSL).
- 0 views
- 24 Mar, 2022
- 1 location
Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma (PCNSL-LEM)
CR or PR after induction chemotherapy will enter the study protocol of lenalidomide maintenance (at a dose of 15 mg per day, on days 1 to 21 of each 28-day cycle) for a maximum of 12 cycles, withdrew
- 0 views
- 12 Mar, 2022
- 1 location
Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy
The purpose of this study is to determine if using a subject's baseline frailty score to guide the dosing of lenalidomide in a combination with dexamethasone and daratumumab (DRd lite).
- 0 views
- 23 Mar, 2022
- 1 location
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of study drugs have on subjects and their cancer, and to evaluate the …
- 0 views
- 04 Oct, 2022
- 1 location
Rituximab Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma
It is a single arm, multicenter, phase 2 study to explore the efficacy and safety study of R2-MTX chemotherapyLenalidomide, Rituximab and Methotrexateas first-line regimens in the treatment of newly diagnosed primary central nervous system lymphoma. Objective response rate is the primary endpoint.
- 0 views
- 01 Jul, 2021
- 1 location
Evaluation iNduction, Consolidation and Maintenance Treatment With Isatuximab , Carfilzomib, LEnalidomide and Dexamethasone
A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984), Carfilzomib, LEnalidomide and Dexamethasone (I-KRd
- 20 views
- 17 Jun, 2022
- 18 locations